Key result
NHE-1 inhibitors attenuate cardiomyocyte hypertrophy and heart failure in preclinical models, suggesting they could emerge as important therapeutic tools for the treatment of heart failure.
Why the study?
Do Na-H exchange (NHE-1) inhibitors attenuate cardiomyocyte hypertrophy and heart failure in preclinical models?
Do Na-H exchange (NHE-1) inhibitors attenuate cardiomyocyte hypertrophy and heart failure in preclinical models?
Preclinical evidence indicates that NHE-1 inhibitors have therapeutic potential to attenuate maladaptive cardiac remodeling and heart failure, particularly after myocardial infarction.
Answers are grounded in this paper and cite their sources.
NHE-1 inhibitors should not yet alter heart failure care; leaves open their potential pending clinical translation.
The Na-H exchanger (NHE) represents a family of transporters which regulate intracellular pH by removing protons in exchange for sodium influx in an electroneutral 1:1 stoichiometric relationship. Six isoforms have thus far been identified with the NHE-1 subtype representing the primary isoform in the cardiac cell. It is well-established that NHE-1 contributes to cardiac injury produced by ischaemia and reperfusion and inhibitors of the antiporter exert excellent cardioprotection. More recent evidence suggests that NHE-1 may also be important for cell growth and may contribute to the maladaptive remodelling which contributes to heart failure particularly the early hypertrophic responses. Evidence from in vitro studies suggest that NHE-1 inhibitors attenuate cardiomyocyte hypertrophy in response to various stimuli whereas in vivo studies report substantial attenuation of both hypertrophy and heart failure by these agents, especially after myocardial infarction. Accordingly, NHE-1 inhibitors could emerge as important therapeutic tools for the attenuation and treatment of heart failure.
No takes yet. Share an insight, caveat, or question.
Morris Karmazyn (2001) conducted a review in Heart failure. Na-H exchange (NHE-1) inhibitors was evaluated. NHE-1 inhibitors attenuate cardiomyocyte hypertrophy and heart failure in preclinical models, suggesting they could emerge as important therapeutic tools for the treatment of heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: